The algorithm could outperform existing noninvasive tools for identifying advanced fibrosis in MASH without producing indeterminate results.

Patients achieve a high 2-year survival and deep MRD-negative remissions with CAR T-cell therapy followed by stem cell transplant in B-cell ALL.

Long-term data suggest stress echocardiography can uncover impaired exercise capacity and predict worse outcomes in patients.

Shared savings reflects continued growth of long-term-care ACOs in Medicare’s value-based models.

New treatment options for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) could enhance patient care and monitoring.

AI, especially deep learning applied to blood smear imaging, can greatly improve the speed and accuracy of leukemia detection and subtype classification.

Mirvetuximab soravtansine, particularly in combination regimens, showed promising efficacy and an acceptable safety profile in recurrent ovarian cancer.

The HIV chatbot was noninferior in increasing self-testing compared with the real-time support by human administrators.

The analysis found that zanubrutinib provides similar progression-free survival to fixed-duration venetoclax plus ibrutinib but with consistently fewer serious side effects, suggesting a more favorable overall safety profile.

Patients with elevated levels of multiple adipokines had the highest risk, the authors found.

New research comparing the safety profiles of the 2 multiple sclerosis therapies suggests ocrelizumab is associated with lower rates of all-cause hospitalization and hypogammaglobulinemia.

Combining genetic features with clinical data improved the performance of a pulmonary fibrosis prediction score for people with rheumatoid arthritis.

Pigment epithelial detachment and hyperreflective foci had better early control in age-related macular degeneration (AMD) when treated with faricimab.

New research reveals ritlecitinib's potential to reverse scarring alopecias by targeting inflammation, offering hope for hair regrowth in autoimmune disorders.

Telehealth has quickly become a central part of the mental health system among younger, higher-income, college-educated, and privately insured patients.

Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and offering convenient self-injection treatment.

Ryan Haumschild, PharmD, MS, MBA, discusses key considerations for pharmacists to ensure access to cutting-edge therapies for patients with cancer.

The latest advancements in idiopathic pulmonary fibrosis (IPF) treatment offer promising efficacy and improved tolerability.

After 8 months of treatment with mavacamten, 5% of patients developed new atrial fibrillation or flutter and 4% developed heart failure.

The expansion of direct-to-consumer (DTC) pharmaceutical manufacturer models and the upcoming TrumpRx launch offer lower costs but create new complexities for patients.

Medicaid expansion has enhanced cancer care in Louisiana, boosting access to treatments like CAR T-cell therapy and improving breast cancer screening initiatives.

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

With ACA subsidies and key CMS payment models ending in 2025, premiums are set to rise, shifting costs to consumers and employers.

A study identifies tumor stage and stoma status as key drivers of diminished quality of life among patients with colorectal cancer.

While artificial intelligence showed empathy and precision in respiratory health care, its equitable adoption is paramount to prevent the widening digital divide, as highlighted at the European Respiratory Society Congress 2025.